Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011044 | 0.88 | CCNT1 (0.49) | ERN1CCNT1CDK9HASPINCYP2A6 | |
| SCHEMBL29935732 | 0.82 | CYP2D6 (0.53) | ERN1CCNT1CDK9HASPINHTT | |
| SCHEMBL844312 | 0.82 | CYP2D6 (0.53) | ERN1CCNT1CDK9HASPINHTT | |
| SCHEMBL30431216 | 0.81 | IMPDH2 (0.49) | ERN1CCNT1CDK9HASPINHTT | |
| SCHEMBL29956340 | 0.81 | ERN1 (0.50) | ERN1CYP2A6KDM4ELMNAALDH1A1 | |
| SCHEMBL30431175 | 0.81 | IMPDH2 (0.49) | ERN1CCNT1CDK9HASPINHTT | |
| SCHEMBL1351597 | 0.81 | ERN1 (0.50) | ERN1CYP2A6KDM4ELMNAALDH1A1 | |
| SCHEMBL27600620 | 0.79 | ERN1 (0.49) | ERN1CYP2A6KDM4ELMNAALDH1A1 | |
| Bromide SCHEMBL8728642 | 0.79 | ERN1 (0.49) | ERN1CYP2A6KDM4ELMNAALDH1A1 | |
| SCHEMBL29955436 | 0.77 | KMT2A (0.46) | ERN1CCNT1CDK9HASPINCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| EP-3307724-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | National University of Singapore (SG) | 2018-04-18 | — | — | EP | disclosed |
| CN-107922383-A | Selective anticancer compound | 新加坡国立大学 | 2018-04-17 | — | — | CN | disclosed |
| WO-2016200339-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-12-15 | — | — | WO | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1831196-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | ERN1 1396/4885CCNT1 3/4885CDK9 101/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | ERN1 1396/4885CCNT1 3/4885CDK9 101/4885 |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ERN1 3462/4885CCNT1 142/4885CDK9 749/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ERN1 2050/4885CCNT1 320/4885CDK9 34/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ERN1 3462/4885CCNT1 142/4885CDK9 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.